Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 80 3-Year EPS without NRI Growth Rate is 0.10% as of Mar. 2026, which is 96% below its 10-year median of 2.50. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €43.73. The stock has 5 warning signs investors should review. Among 789 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 63.12% on this metric.
During the past 12 months, Dermapharm Holding SE's average EPS without NRI Growth Rate was 39.60% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 0.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -1.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Dermapharm Holding SE was 38.90% per year. The lowest was -17.70% per year. And the median was 2.50% per year.
Dermapharm Holding SE (CHIX:DMPd) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Dermapharm Holding SE 3-Year EPS without NRI Growth Rate Related Terms
CHIX:DMPD vs ZTS, UTHR: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's 3-Year EPS without NRI Growth Rate falls into.
Dermapharm Holding SE 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.10% mean?
Dermapharm Holding SE (CHIX:DMPD) has a 3-Year EPS without NRI Growth Rate of 0.10% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Dermapharm Holding SE and its competitors. This is 96% below median its historical median of 2.50. According to the industry distribution chart, Dermapharm Holding SE ranks #498 out of 789 companies in the Drug Manufacturers industry, placing it in the top 63.1%.
Is Dermapharm Holding SE's 3-Year EPS without NRI Growth Rate too high?
Dermapharm Holding SE's current 3-Year EPS without NRI Growth Rate of 0.10% is 96% below median its 10-year median of 2.50. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Dermapharm Holding SE's value of 0.10% is 99% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #498 out of 789 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #498 out of 789 companies for 3-Year EPS without NRI Growth Rate. This places Dermapharm Holding SE in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Dermapharm Holding SE's value of 0.10% is 99% below this benchmark. While the company's 10-year median is 2.50 vs. the industry median of 9.60, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current 3-Year EPS without NRI Growth Rate of 0.10% is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current 3-Year EPS without NRI Growth Rate is 0.10%, which is 96% below median its own 10-year median of 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current 3-Year EPS without NRI Growth Rate of 0.10%. The stock's GF Value™ is €43.73, compared to a current price of €46.18 — trading 5.6% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.10%, which is 96% below median its 10-year median of 2.50 and 99% below the Drug Manufacturers industry median of 9.60. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current 3-Year EPS without NRI Growth Rate is 0.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 5.6% above its estimated GF Value™ of €43.73.
Key valuation signals for CHIX:DMPD:
3-Year EPS without NRI Growth Rate: 0.10% (96% below median its 10-year median of 2.50)
GF Value™: €43.73 vs. price of €46.18 (5.6% above fair value)
Industry Position: 99% below the Drug Manufacturers median (#498 of 789)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
